Vanderbilt University Medical Center: Tirzepatide Trial Shows Additional 21.1% Weight Loss Following Intensive Lifestyle Intervention
October 18, 2023
October 18, 2023
NASHVILLE, Tennessee, Oct. 18 (TNSres) -- Vanderbilt University Medical Center issued the following news:
By Jill Clendening
A phase 3 clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.
The findings of the SURMOUNT-3 study, sponsored by pharmaceuti . . .
By Jill Clendening
A phase 3 clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.
The findings of the SURMOUNT-3 study, sponsored by pharmaceuti . . .